Vivo Capital LLC Invests $22.04 Million in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Vivo Capital LLC purchased a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 8,888,888 shares of the biotechnology company's stock, valued at approximately $22,044,000. Aclaris Therapeutics accounts for about 2.5% of Vivo Capital LLC's portfolio, making the stock its 7th largest position. Vivo Capital LLC owned approximately 12.44% of Aclaris Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its holdings in shares of Aclaris Therapeutics by 211.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 239,595 shares of the biotechnology company's stock valued at $594,000 after purchasing an additional 162,785 shares in the last quarter. Marshall Wace LLP acquired a new stake in Aclaris Therapeutics in the fourth quarter valued at about $6,532,000. Walleye Capital LLC bought a new position in Aclaris Therapeutics in the fourth quarter valued at about $1,783,000. XTX Topco Ltd acquired a new position in Aclaris Therapeutics during the fourth quarter worth about $111,000. Finally, Raymond James Financial Inc. bought a new position in shares of Aclaris Therapeutics in the fourth quarter worth about $383,000. 98.34% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. StockNews.com cut shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 8th. Scotiabank assumed coverage on Aclaris Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target for the company. Finally, Cantor Fitzgerald started coverage on Aclaris Therapeutics in a report on Tuesday, March 18th. They issued an "overweight" rating for the company. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Aclaris Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.67.

Aclaris Therapeutics Stock Up 5.5 %

ACRS traded up $0.07 during midday trading on Friday, hitting $1.34. 508,812 shares of the company were exchanged, compared to its average volume of 1,189,433. The firm's 50 day moving average price is $1.56 and its 200-day moving average price is $2.23. Aclaris Therapeutics, Inc. has a 1-year low of $0.95 and a 1-year high of $5.17. The firm has a market capitalization of $145.10 million, a P/E ratio of -2.58 and a beta of 0.53.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.